Equine herpesvirus 2 (EHV-2) infection in thoroughbred horses in Argentina by Craig, María I et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Veterinary Research
Open Access Research article
Equine herpesvirus 2 (EHV-2) infection in thoroughbred horses in 
Argentina
María I Craig*, María E Barrandeguy and Fernando M Fernández
Address: Instituto de Virología, Centro de Investigación en Ciencias Veterinarias y Agronómicas (CICVyA), INTA, CC 25, (1712) Castelar, Buenos 
Aires, Argentina
Email: María I Craig* - bcraig@cicv.inta.gov.ar; María E Barrandeguy - mbarrandeguy@cicv.inta.gov.ar; 
Fernando M Fernández - ffernandez@cicv.inta.gov.ar
* Corresponding author    
Abstract
Background:  Equine herpesvirus 2 is a gamma-herpesvirus that infects horses worldwide.
Although EHV-2 has been implicated in immunosuppression in foals, upper respiratory tract
disease, conjunctivitis, general malaise and poor performance, its precise role as a pathogen
remains uncertain. The purpose of the present study was to analyse the incidence of EHV-2 in an
Argentinean horse population and correlate it with age and clinical status of the animals.
Results: A serological study on 153 thoroughbred racing horses confirmed the presence of EHV-
2 in the Argentinean equine population. A virus neutralization test showed a total of 79.7 % animals
were sero-positive for EHV-2. An increase in antibodies titre with age as well as infection at earlier
ages were observed.
EHV-2 was isolated from 2 out of 22 nasal swabs from horses showing respiratory symptoms. The
virus grew slowly and showed characteristic cytopathic effect after several blind passages on RK13
cells. The identity of the isolates was confirmed by nested PCR and restriction enzyme assay (REA).
Conclusion: This is the first report on the presence of EHV-2 in Argentina and adds new data to
the virus distribution map. Though EHV-2 was isolated from foals showing respiratory symptoms,
further studies are needed to unequivocally associate this virus with clinical symptoms.
Background
Equine herpesvirus 2 (EHV-2) is a slowly growing, cell-
associated gamma-herpesvirus. This virus is widespread
throughout the equine population and has been isolated
from horses of different countries like United Kingdom
[1], Japan [2], Australia [3], New Zealand [4], Switzerland
[5], Germany [6,7], United States [8,9], Canada [10],
Hungary [11] and more recently, from Poland [12].
Although its role as a pathogen is controversial, some
authors have reported its association with upper respira-
tory tract disease, inappetance, lymphadenopathy, immu-
nosuppression, keratoconjunctivitis, general malaise and
poor performance [8,13-15,7,16].
Equine Influenza Virus and Equine Herpesvirus 4 (EHV-
4) are the most common viral agents related to respiratory
disease in Argentina (Dr. Barrandeguy, personal commu-
nication). These and other respiratory viruses as Adenovi-
rus, Equine herpesvirus 1 (EHV-1), Arteritis Virus and
Rhinovirus, are usually checked in the diagnostic routine
of our laboratory but no records about EHV-2 isolation or
frequency of sero-positive samples were available.
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The purpose of the present study was to analyse the pres-
ence of EHV-2 in an Argentinean horse population and to
correlate its incidence with age and presence of respiratory
symptoms.
Results and discussion
Sero-prevalence of EHV-2 was calculated on one hundred
and fifty-three (153) thoroughbred racing horses by a
neutralization test (NT). Cross reactivity with EHV-5 was
not checked in this study. The percentage of sero-preva-
lence to EHV-2 was 79.7% (122/153). Sera samples were
grouped according to the clinical status into animals with
symptoms (fever, cough, nasal discharge) or clinically
healthy. Again, each of these groups was divided accord-
ing to the animal age in older or younger than 1 year old.
The arithmetical mean of the antibody titres was calcu-
lated for each of these four groups. Mean antibody titres
between older and younger than 1 year old animals both,
with and without clinical symptoms were statistically
compared. Mean values for the older horses (1.28 > 1.02)
were significantly (p < 0.05) higher than for the younger
ones. These results agree with the observations of other
authors [17] about the increase in antibodies titre with
age. Within the older than 1-year group, the mean titre in
the group with clinical symptoms was higher (1.34>1.22)
though not significant. However, mean titre values were
significantly (p < 0.05) higher (1.19>0.85) in the group
with clinical symptoms within the younger than 1 year
group (Table 1). This difference might be related to the
early exposure to this agent.
Our results suggest the virus is circulating with a high
prevalence on the analysed equine population, in accord-
ance with other sero-prevalence data [17,18], and confirm
previous reports [19] about the acquisition of EHV-2 at
earlier ages.
Taking into account the relatively high percentage of sero-
prevalence and the association of EHV-2 with respiratory
disease [16], the isolation of this viral agent from horses
showing different respiratory symptomathology was car-
ries out. Twenty-two (22) nasal swabs from horses, aged
between 6 months and 2 years old, displaying respiratory
symptoms were checked for the respiratory viruses com-
monly analysed in the laboratory routine, and none of
them resulted positive for these viruses. Only two (2)
nasal swab samples, named E1 and E2, showed CPE after
the third blind passage. Some authors reported the pres-
ence of vacuoles in RK-13 cells infected with EHV-2 iso-
lates [20] while others described various CPE forms
depending on the virus isolate and cell type [21]. In our
isolate, CPE was characterized by rounded cells, syncytia
and vacuolized cell aggregates with suited partial cell
membrane fusion. The late development of CPE referred
to a slow growing viral agent.
In order to identify these two isolates, two simple tech-
niques like EM and IIFA were first used. The particle mor-
phology observed by EM showed a size corresponding to
a typical herpesvirus (data not shown). The IIFA showed
fluorescence signals on cells infected with EHV-2 refer-
ence strain LK, E1 and E2. Mock-infected cells were nega-
tive (data not shown). As the polyclonal antiserum used
for the staining could have cross reaction with EHV-5,
another member of the gamma-herpesvirinae subfamily
that shows growth characteristics similar to EHV-2 [22], a
virus specific nested PCR and a restriction enzyme analy-
sis (REA) were performed.
Nested PCR was carried out on E1 and E2 samples as
described in Methods. After the second round, both isola-
tions showed a band of around 600 bp (Figure 1), as the
one displayed by the positive control.
EHV-5 identity of the isolations was unequivocally
excluded by REA. As shown in Figure 2, the patterns after
digestion with Hind III and Eco RI of the isolates and a
control EHV-5 were completely different.
As it was specified by others authors [23,24], EHV-2 was
described as a virus with a high genomic variation. In our
experiments, the restriction patterns of the isolates were
different to those of T400 and LK4. Moreover, E1 and E2
resulted identical to each other and very similar to strain
Table 1: Distribution of serum samples according to age and clinical status
With symptoms Antibodies Clinically healthy Antibodies
Animals Sero-negative Sero-positive (Mean titre)a Sero-negative Sero-positive (Mean titre)a
Older than 1 year old 53 2 1 . 3 4 34 0 1 . 2 2
Younger than 1 year old 3 26 1.19 18 26 0.85*
Total (n) 66 87
n: number of samples
a: arithmetical media of Ab titre (Reed and Muench)
*: Significantly different (p < 0.05)BMC Veterinary Research 2005, 1:9 http://www.biomedcentral.com/1746-6148/1/9
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H40. Both, E1 and E2 belonged to the same stud farm and
were probably epidemiologically related.
Conclusion
Although EHV-2 has been reported in equine populations
worldwide, no reports about its prevalence in Argentina
were available. In this study, serological data and virus
isolation provided a clear evidence for the presence of this
agent on the studied horse population. In horses younger
than 1 year old but not in the older ones, serological data
correlated with the presence of clinical symptoms.
Though viral agents associated with respiratory disease
were discarded, no bacterial analysis was done in the stud-
ied samples. Further studies are necessary to correlate
EHV-2 with the respiratory disease. The EHV-2 identity of
the isolated viruses was finally confirmed by the use of a
nested PCR and a restriction enzyme assay. This is the first
report of EHV-2 isolation in Argentina and adds new data
to the EHV-2 distribution map.
Methods
Cells
RK-13 (ATTCC CCL 37) cell monolayers were grown with
Eagle 's- minimum essential medium (MEM-E) supple-
mented with 100 UI/ml penicillin, 60 µg/ml streptomy-
cin, 50 µg/ml gentamycin and 10% FCS. Subsequently,
the cells were maintained with MEM-E supplemented
with same concentrations of antibiotics and 2% FCS.
Virus
EHV-2 strains LK (ATTCC VR 701), H40 (NVSL Ames
Iowa), LK4 and T400 as well as, EHV-5 strain P48, were
kindly supplied by Dr. Borchers (Institut für Virologie,
Freie Universität, Berlin-Germany).
Samples
Sera
Serum samples were obtained from one hundred and fifty
three (153) thoroughbred racing horses, aged between 6
months and 2 years old.
Nasal swabs
Nasal swabs from twenty-two horses showing respiratory
symptoms like nasal discharge, cough and fever, were
used in our research. Samples were collected with a cotton
swab and transferred to a tube containing 3 ml of E-MEM
supplemented with 2% FCS and antibiotics. Clarification
was performed by centrifugation at 3000 rpm (Hermle Z
513 K) for 15 min. Each sample was aliquoted and stored
at -70°C until use.
Nested PCR on nasal swab samples from foals with respira- tory symptoms Figure 1
Nested PCR on nasal swab samples from foals with 
respiratory symptoms. Nested PCR amplification prod-
ucts from two equines (E1 and E2) showing respiratory 
symptoms were analysed by gel electrophoresis. DNA was 
extracted from original nasal swabs; DNA from the suspen-
sion was used as template in the first round. Genomic DNA 
from EHV-2 strain LK was used as a PCR positive control 
(PCR+) and H20 as negative control (PCR -). DNA marker 
φX-174 Hae and λ-RF/Hind III is seen in lane M.
Restriction enzyme assay profile of EHV-2 isolates and refer- ence strains Figure 2
Restriction enzyme assay profile of EHV-2 isolates 
and reference strains. EHV-2 isolates (E1 and E2), EHV-2 
strains H40, T400, and LK4, and EHV-5 strain P48, were 
amplified in RK-13 cell monolayer. Viral DNA was purified by 
Genomic-tip 20/G column, digested with Hind III and Eco RI 
and analysed by gel electrophoresis. DNA marker φX-174 
Hae III and λ-RF/Hind III is seen in lane M.BMC Veterinary Research 2005, 1:9 http://www.biomedcentral.com/1746-6148/1/9
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Neutralization test
This assay was performed on 96 wells RK-13 cell monol-
ayer, where serial four-fold dilutions of complement-inac-
tivated serum were incubated with 100 ID50 of LK strain
for 4 hs at 37°C as described elsewhere [25]. After 7 incu-
bation days, antibody titres were calculated by Reed and
Muench formula [26]. Sera that protected 100% of the cell
monolayer at the lower dilution assayed were considered
positive. An EHV-2 positive horse reference serum used as
positive control, was kindly supplied by Dr. Borchers.
Indirect immunofluorescence assay
Trypsinised virus infected cells were seeded on IFA micro
slides and fixed with ice-cold acetone for 30 min. A poly-
clonal EHV-2 specific rabbit serum (341 EDV 8301, NVSL
Ames Iowa) was added and incubated in a moist chamber
al 37°C for 1 h. Fluorescein conjugated rabbit antiserum
(KPL Kikergaard and Perry laboratories) was used to
reveal the reaction. EHV-2 LK strain infected RK-13 and
non-infected cells were used as positive and negative assay
controls, respectively.
Electron microscopy
Cell cultures showing 70% CPE were trypsinised and son-
icated for 30 seconds in a Sonicator XL (Hert System) and
spinned at 3000 × g during 10 minutes to eliminate cell
debris. The supernatant was centrifuged at 14000 × g for 1
h 30 minutes and the resulting pellet was resuspended
with a saline buffer solution and stained with 2% phos-
photungstate acid.
Virus isolation
All nasal swab samples were previously checked for the
presence of equine viruses associated with respiratory dis-
ease. Equine adenovirus, rhinovirus, arteritis virus, equine
herpesvirus 1 and 4, were checked by isolation in cell tis-
sue culture while equine influenza virus was assayed using
embryonated eggs. Once it was confirmed that all the
samples were negative for the mentioned viruses, the pres-
ence of EHV-2 was analysed. Briefly, 0.5 ml of each sam-
ple was inoculated onto confluent RK-13 monolayers in
25 cm2 flask (NUNC™, Denmark). After an adsorption
period at 37°C for 1 h, the inoculum was removed and
cells were maintained at 37°C at an atmosphere of 5%
CO2 for 7 days with periodic microscopical examination.
After this time period, a blind passage was made if CPE
was absent. Cell monolayers were thawed and freezed
three times and an aliquot of the suspension was passed
on to fresh cell culture. The samples were considered neg-
ative after the forth-blind passage.
Nested PCR
The nested PCR used in this study amplifies a 620 bp
sequence located upstream of the ORF coding for vIL-10
[27].
Original nasal swab samples were centrifuged for 10 min
at 15,000 × g as described elsewhere [27]. Briefly, resulting
pellets were diluted in 50 µl digestion buffer (50 mM Tris
pH 8.5; 1 mM EDTA; 0.5% Tween 20) plus 1.5 µl Protei-
nase K (10 mg/ml, Sigma) and incubated at 56°C for 3 h,
boiled for 10 min at 95°C to inactivate the proteinase K
and the supernatant used for nPCR. PCR conditions were
optimised using purified viral DNA from the EHV-2 LK
strain obtained as described below. The PCR mix (50 µl)
contained 0.2 mM dNTPs, 0.4 µM of each primer [27], 1.5
U Taq polymerase (QIAGEN), 1 × reaction buffer (QIA-
GEN) and 10 µl of DNA suspension obtained from the
original nasal swab sample. The optimal annealing tem-
perature for each of the two primer pairs was 60°C.
Cycling was carried out using a Biometra trio-thermblock
(Biometra®) with 35 amplification cycles consisting of
denaturation at 94°C for 30 sec, annealing at 60°C for 30
sec and extension at 72°C for 1 min. For the second round
of this nested PCR, 3 µl from the first PCR reaction were
amplified with the inner pair of primers using the same
cycle as before. Purified viral DNA from the EHV-2 LK
strain was used as a PCR positive control.
Restriction enzyme assay
Viral DNA was obtained from RK-13 cells infected with
EHV-2 isolates and also with EHV-2 reference strains H40,
LK4, T400 and EHV-5 (P48). Viruses were pelleted from
cell culture supernatant by centrifugation through a 30%
sucrose cushion at 24,000 × g for 1 h 30 min. Pellets were
resuspended with DNA buffer (10 mM MgCl2, 2 mM
CaCl2, 200 mM Tris pH 7.4) and treated with RNAse (10
mg/ml) and DNAse I (2 mg/360 µl) at 37°C for 1 h. Sub-
sequently, the pellets were treated with EDTA (0.2 M), 1%
sodium dodecyl sulphate and proteinase K (10 mg/ml)
(Boehringer, Manheim). Finally, DNA was purified by
Genomic-tip 20/G column (QIAGEN, Hilden, Germany)
according to the manufacturer's instructions. Aliquots of
200 ng of the obtained purified viral DNA were digested
overnight at 37°C with Eco RI and Hind III. The fragments
were separated by electrophoresis through 1% agarose gel
and stained with ethidium bromide.
Statistical analysis
Two (2) ways ANOVA [28] followed by post hoc compar-
isons (Tukey HSD for unequal N, Spiotvoll/Stoline test)
[29] were used.
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